These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 34532977)

  • 21. Deep Artificial Neural Networks and Neuromorphic Chips for Big Data Analysis: Pharmaceutical and Bioinformatics Applications.
    Pastur-Romay LA; Cedrón F; Pazos A; Porto-Pazos AB
    Int J Mol Sci; 2016 Aug; 17(8):. PubMed ID: 27529225
    [TBL] [Abstract][Full Text] [Related]  

  • 22. From Target to Drug: Generative Modeling for the Multimodal Structure-Based Ligand Design.
    Skalic M; Sabbadin D; Sattarov B; Sciabola S; De Fabritiis G
    Mol Pharm; 2019 Oct; 16(10):4282-4291. PubMed ID: 31437001
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Concepts of Artificial Intelligence for Computer-Assisted Drug Discovery.
    Yang X; Wang Y; Byrne R; Schneider G; Yang S
    Chem Rev; 2019 Sep; 119(18):10520-10594. PubMed ID: 31294972
    [TBL] [Abstract][Full Text] [Related]  

  • 24. From machine learning to deep learning: progress in machine intelligence for rational drug discovery.
    Zhang L; Tan J; Han D; Zhu H
    Drug Discov Today; 2017 Nov; 22(11):1680-1685. PubMed ID: 28881183
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Trends in Deep Learning for Property-driven Drug Design.
    Born J; Manica M
    Curr Med Chem; 2021; 28(38):7862-7886. PubMed ID: 34325627
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Exploring Tunable Hyperparameters for Deep Neural Networks with Industrial ADME Data Sets.
    Zhou Y; Cahya S; Combs SA; Nicolaou CA; Wang J; Desai PV; Shen J
    J Chem Inf Model; 2019 Mar; 59(3):1005-1016. PubMed ID: 30586300
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Beyond the hype: deep neural networks outperform established methods using a ChEMBL bioactivity benchmark set.
    Lenselink EB; Ten Dijke N; Bongers B; Papadatos G; van Vlijmen HWT; Kowalczyk W; IJzerman AP; van Westen GJP
    J Cheminform; 2017 Aug; 9(1):45. PubMed ID: 29086168
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Quantitative structure-activity relationship: promising advances in drug discovery platforms.
    Wang T; Wu MB; Lin JP; Yang LR
    Expert Opin Drug Discov; 2015 Dec; 10(12):1283-300. PubMed ID: 26358617
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Spectrum of deep learning algorithms in drug discovery.
    Piroozmand F; Mohammadipanah F; Sajedi H
    Chem Biol Drug Des; 2020 Sep; 96(3):886-901. PubMed ID: 33058458
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Proteochemometrics - recent developments in bioactivity and selectivity modeling.
    Bongers BJ; IJzerman AP; Van Westen GJP
    Drug Discov Today Technol; 2019 Dec; 32-33():89-98. PubMed ID: 33386099
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Predictive QSAR modeling workflow, model applicability domains, and virtual screening.
    Tropsha A; Golbraikh A
    Curr Pharm Des; 2007; 13(34):3494-504. PubMed ID: 18220786
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hyperbolic relational graph convolution networks plus: a simple but highly efficient QSAR-modeling method.
    Wu Z; Jiang D; Hsieh CY; Chen G; Liao B; Cao D; Hou T
    Brief Bioinform; 2021 Sep; 22(5):. PubMed ID: 33866354
    [TBL] [Abstract][Full Text] [Related]  

  • 33. NL MIND-BEST: a web server for ligands and proteins discovery--theoretic-experimental study of proteins of Giardia lamblia and new compounds active against Plasmodium falciparum.
    González-Díaz H; Prado-Prado F; Sobarzo-Sánchez E; Haddad M; Maurel Chevalley S; Valentin A; Quetin-Leclercq J; Dea-Ayuela MA; Teresa Gomez-Muños M; Munteanu CR; José Torres-Labandeira J; García-Mera X; Tapia RA; Ubeira FM
    J Theor Biol; 2011 May; 276(1):229-49. PubMed ID: 21277861
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evolutionary computation and QSAR research.
    Aguiar-Pulido V; Gestal M; Cruz-Monteagudo M; Rabuñal JR; Dorado J; Munteanu CR
    Curr Comput Aided Drug Des; 2013 Jun; 9(2):206-25. PubMed ID: 23700999
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A natural language processing approach based on embedding deep learning from heterogeneous compounds for quantitative structure-activity relationship modeling.
    Bouhedjar K; Boukelia A; Khorief Nacereddine A; Boucheham A; Belaidi A; Djerourou A
    Chem Biol Drug Des; 2020 Sep; 96(3):961-972. PubMed ID: 33058460
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Machine Learning Applied to the Modeling of Pharmacological and ADMET Endpoints.
    Göller AH; Kuhnke L; Ter Laak A; Meier K; Hillisch A
    Methods Mol Biol; 2022; 2390():61-101. PubMed ID: 34731464
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Artificial intelligence: Deep learning in oncological radiomics and challenges of interpretability and data harmonization.
    Papadimitroulas P; Brocki L; Christopher Chung N; Marchadour W; Vermet F; Gaubert L; Eleftheriadis V; Plachouris D; Visvikis D; Kagadis GC; Hatt M
    Phys Med; 2021 Mar; 83():108-121. PubMed ID: 33765601
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Artificial intelligence in drug design.
    Zhong F; Xing J; Li X; Liu X; Fu Z; Xiong Z; Lu D; Wu X; Zhao J; Tan X; Li F; Luo X; Li Z; Chen K; Zheng M; Jiang H
    Sci China Life Sci; 2018 Oct; 61(10):1191-1204. PubMed ID: 30054833
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Applications of Quantitative Structure-Activity Relationships (QSAR) based Virtual Screening in Drug Design: A Review.
    Achary PGR
    Mini Rev Med Chem; 2020; 20(14):1375-1388. PubMed ID: 32348219
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Quantitative structure-activity relationship models for compounds with anticonvulsant activity.
    Bellera CL; Talevi A
    Expert Opin Drug Discov; 2019 Jul; 14(7):653-665. PubMed ID: 31072145
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.